PE20211389A1 - Compuestos de bencenosulfonamida y su uso como agentes terapeuticos - Google Patents
Compuestos de bencenosulfonamida y su uso como agentes terapeuticosInfo
- Publication number
- PE20211389A1 PE20211389A1 PE2020001990A PE2020001990A PE20211389A1 PE 20211389 A1 PE20211389 A1 PE 20211389A1 PE 2020001990 A PE2020001990 A PE 2020001990A PE 2020001990 A PE2020001990 A PE 2020001990A PE 20211389 A1 PE20211389 A1 PE 20211389A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- halo
- amino
- benzenesulfonamide
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684436P | 2018-06-13 | 2018-06-13 | |
| PCT/US2019/037011 WO2019241533A1 (en) | 2018-06-13 | 2019-06-13 | Benzenesulfonamide compounds and their use as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211389A1 true PE20211389A1 (es) | 2021-07-27 |
Family
ID=67138087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001990A PE20211389A1 (es) | 2018-06-13 | 2019-06-13 | Compuestos de bencenosulfonamida y su uso como agentes terapeuticos |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10745392B2 (https=) |
| EP (1) | EP3807281A1 (https=) |
| JP (3) | JP7371029B2 (https=) |
| KR (1) | KR102833674B1 (https=) |
| CN (1) | CN112262142B (https=) |
| AU (1) | AU2019285184B2 (https=) |
| BR (1) | BR112020024729A2 (https=) |
| CA (1) | CA3103600A1 (https=) |
| CL (1) | CL2020003197A1 (https=) |
| CR (1) | CR20200613A (https=) |
| EA (1) | EA202092719A1 (https=) |
| EC (1) | ECSP20079861A (https=) |
| IL (1) | IL278949B2 (https=) |
| JO (1) | JOP20200304A1 (https=) |
| MA (1) | MA52888A (https=) |
| MX (1) | MX2020013317A (https=) |
| NI (1) | NI202000098A (https=) |
| PE (1) | PE20211389A1 (https=) |
| PH (1) | PH12020552111A1 (https=) |
| SA (1) | SA520420768B1 (https=) |
| SG (1) | SG11202011862PA (https=) |
| UA (1) | UA127024C2 (https=) |
| WO (1) | WO2019241533A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3458449T3 (pl) * | 2016-05-20 | 2025-06-23 | Xenon Pharmaceuticals Inc. | Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| US10745392B2 (en) * | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
| EP4655291A2 (en) * | 2023-01-26 | 2025-12-03 | Merck Sharp & Dohme LLC | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels background |
| CN117510431A (zh) * | 2023-11-08 | 2024-02-06 | 浙江雅辰药物科技股份有限公司 | 一种异噻唑-3-酮及其衍生物、合成方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| EP0981327B1 (en) | 1997-05-07 | 2002-11-06 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| DE19907385A1 (de) | 1999-02-20 | 2000-08-24 | Boehringer Ingelheim Pharma | Neue substituierte 3-Phenoxy- und 3-Phenylalkyloxy-2-phenyl-propylamine |
| JP2003504401A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
| JP2005162726A (ja) | 2003-01-24 | 2005-06-23 | Tanabe Seiyaku Co Ltd | ピラゾロピリミジン化合物およびその製法 |
| WO2004092123A2 (en) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| JP2009513523A (ja) | 2003-07-08 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物 |
| US8202861B2 (en) | 2003-08-08 | 2012-06-19 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| JP2008524244A (ja) | 2004-12-17 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | 水酸化ステロイド脱水素酵素阻害剤 |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| CA2624726A1 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| NZ593074A (en) | 2005-12-21 | 2012-04-27 | Vertex Pharma | sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels |
| EP2054385A2 (en) | 2006-08-15 | 2009-05-06 | F. Hoffmann-Roche AG | Phenyl, pyridine and quinoline derivatives |
| US7968556B2 (en) | 2006-10-19 | 2011-06-28 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| US8853250B2 (en) | 2007-07-13 | 2014-10-07 | Icagen, Inc. | Sodium channel inhibitors |
| CA2693588C (en) | 2007-07-13 | 2015-11-17 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009013171A2 (en) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2009099177A1 (ja) | 2008-02-06 | 2009-08-13 | Taisho Pharmaceutical Co., Ltd. | アミノイミダゾール誘導体 |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| RU2011103451A (ru) | 2008-07-01 | 2012-08-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| WO2010029300A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Bis aromatic compounds for use in the treatment of inflammation |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| EP2606051B1 (en) | 2010-08-20 | 2016-10-05 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| JP2014532660A (ja) | 2011-10-28 | 2014-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物 |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| CN104718188B (zh) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| KR102038607B1 (ko) | 2012-10-15 | 2019-10-30 | 주식회사 대웅제약 | 소디움 채널 차단제, 이의 제조방법 및 이의 용도 |
| EP2911668A4 (en) | 2012-10-26 | 2016-07-20 | Merck Sharp & Dohme | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-CONTROLLED SODIUM CHANNELS |
| JP2015535252A (ja) | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物 |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| WO2014201173A1 (en) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| JP6407285B2 (ja) | 2013-09-09 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| UA120353C2 (uk) | 2013-09-10 | 2019-11-25 | Хромоселл Корпорейшн | Модулятори натрієвого каналу для лікування болю і діабету |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
| AU2014370407B2 (en) | 2013-12-23 | 2018-03-29 | Purdue Pharma L.P. | Indazoles and use thereof |
| WO2016177340A1 (zh) | 2015-05-05 | 2016-11-10 | 上海海雁医药科技有限公司 | 双环取代的苯磺酰胺衍生物、其制法与医药上的用途 |
| US10519147B2 (en) | 2015-12-18 | 2019-12-31 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| EP3484464B1 (en) | 2016-03-22 | 2020-10-28 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
| PL3458449T3 (pl) * | 2016-05-20 | 2025-06-23 | Xenon Pharmaceuticals Inc. | Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne |
| US10836758B2 (en) | 2016-10-27 | 2020-11-17 | Bristol-Myers Squibb Company | Acyl sulfonamide NaV1.7 inhibitors |
| WO2018093694A1 (en) * | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN110325531B (zh) * | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
-
2019
- 2019-06-13 US US16/440,459 patent/US10745392B2/en active Active
- 2019-06-13 MA MA052888A patent/MA52888A/fr unknown
- 2019-06-13 CN CN201980039029.1A patent/CN112262142B/zh active Active
- 2019-06-13 EP EP19735024.2A patent/EP3807281A1/en active Pending
- 2019-06-13 UA UAA202008102A patent/UA127024C2/uk unknown
- 2019-06-13 BR BR112020024729-4A patent/BR112020024729A2/pt unknown
- 2019-06-13 WO PCT/US2019/037011 patent/WO2019241533A1/en not_active Ceased
- 2019-06-13 SG SG11202011862PA patent/SG11202011862PA/en unknown
- 2019-06-13 CA CA3103600A patent/CA3103600A1/en active Pending
- 2019-06-13 AU AU2019285184A patent/AU2019285184B2/en active Active
- 2019-06-13 PE PE2020001990A patent/PE20211389A1/es unknown
- 2019-06-13 CR CR20200613A patent/CR20200613A/es unknown
- 2019-06-13 JP JP2020568796A patent/JP7371029B2/ja active Active
- 2019-06-13 EA EA202092719A patent/EA202092719A1/ru unknown
- 2019-06-13 KR KR1020217000602A patent/KR102833674B1/ko active Active
- 2019-06-13 IL IL278949A patent/IL278949B2/en unknown
- 2019-06-13 MX MX2020013317A patent/MX2020013317A/es unknown
- 2019-12-13 JO JOP/2020/0304A patent/JOP20200304A1/ar unknown
-
2020
- 2020-07-13 US US16/927,178 patent/US11325902B2/en active Active
- 2020-12-09 CL CL2020003197A patent/CL2020003197A1/es unknown
- 2020-12-09 PH PH12020552111A patent/PH12020552111A1/en unknown
- 2020-12-10 NI NI202000098A patent/NI202000098A/es unknown
- 2020-12-10 EC ECSENADI202079861A patent/ECSP20079861A/es unknown
- 2020-12-10 SA SA520420768A patent/SA520420768B1/ar unknown
-
2023
- 2023-08-08 JP JP2023129150A patent/JP2023138672A/ja not_active Withdrawn
-
2025
- 2025-05-30 JP JP2025090964A patent/JP2025128218A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211389A1 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapeuticos | |
| PE20180227A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| MA64510B1 (fr) | Agonistes du récepteur glp-1 et leurs utilisations | |
| PE20190518A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| ECSP21013035A (es) | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapéuticos | |
| AR109596A1 (es) | Compuestos pirazolopiridina y sus usos | |
| PE20211478A1 (es) | Formas cristalinas novedosas | |
| PE20211641A1 (es) | Compuestos de isoxazolina para controlar plagas de invertebrados | |
| MA53170A (fr) | Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1 | |
| CO2019005552A2 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
| MX2018013985A (es) | Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos. | |
| AR071385A1 (es) | Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia. | |
| AR104642A1 (es) | Compuestos carboximidamida derivados de bencimidazol e imidazopiridina | |
| ECSP055636A (es) | Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa | |
| AR079554A1 (es) | Indazoles aminotiazolona sustituidos moduladores de receptores alfa relacionados con estrogenos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar artritis, diabetes, dislipemias y otras enfermedades. | |
| CO2021011023A2 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
| MA40865B1 (fr) | Thiazoles à substitution amide utilisés comme modulateurs de rorgammat | |
| BR112022018123A2 (pt) | Uso de concentrados de suspoemulsão à base de óleo para redução de desvio durante a aplicação por pulverização | |
| MA43400B1 (fr) | Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2 | |
| PE20181522A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| MA40863B1 (fr) | Thiazoles en tant que modulateurs de roryt | |
| AR078856A1 (es) | Composiciones locales de emulsion anestesica y metodos para la fabricacion y utilizacion de las mismas | |
| MX390507B (es) | Compuestos de amida y su uso. | |
| PE20090961A1 (es) | Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor | |
| CO2021007442A2 (es) | Compuesto de 1,3,4-oxadiazolona y fármaco |